OMOLOLA FAGBOYEGUN: Open Payments
NPI 1982322814 · MANSFIELD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,551 in 54 payments from 9 companies in 2025. Trend: 2023 $1,726 · 2024 $1,795 · 2025 $2,551
Food & beverage: $2,441Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 27 | $896 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $388 |
| Janssen Pharmaceuticals, Inc | 5 | $311 |
| Janssen Scientific Affairs, LLC | 2 | $286 |
| Neurocrine BioSciences, Inc. | 4 | $218 |
| Luye Pharma (USA) Ltd. | 5 | $207 |
| Otsuka America Pharmaceutical, Inc. | 4 | $173 |
| Alkermes, Inc. | 2 | $56 |
| ABBVIE INC. | 1 | $16 |
Products named: INVEGA SUSTENNA, AUSTEDO XR, CAPLYTA, UZEDY, INGREZZA, ERZOFRI EXTENDED-RELEASE, ABILIFY MAINTENA, ARISTADA.
Industry payments across TX — which companies pay providers there.
